Merger partner Nuclea signs MOU with Utah to explore nuclear test reactor site, advancing microreactor demonstration

summarizeSummary

Nuclea Energy, Mangoceuticals' merger partner, signed an MOU with Utah to explore a nuclear test reactor site, advancing its microreactor technology toward demonstration.

check_boxKey Events · M&A and Partnerships · MGRX

• MOU Signed with Utah OED

  Nuclea Energy USA Inc. signed a memorandum of understanding with the Utah Office of Energy Development to explore siting a nuclear test reactor at the Utah San Rafael Energy Lab, supporting engagement with the DOE and NRC.

• Advances Morpheus Microreactor

  The MOU aims to accelerate the Morpheus microreactor toward demonstration and commercial deployment, leveraging Utah's nuclear innovation hub.

• Merger Context

  This progress follows the July 30, 2026 definitive business combination agreement, where Nuclea will reverse-merge into Mangoceuticals, leaving existing MGRX shareholders with approximately 4% of the combined company.

• Next Steps

  Completion of the business combination remains subject to stockholder and regulatory approvals; the MOU does not alter the merger timeline but adds a tangible development milestone.

auto_awesomeAnalysis · MGRX · Industrial Applications And Services

A concrete step toward demonstrating the Morpheus microreactor arrived when Nuclea Energy—the private nuclear startup set to reverse-merge into Mangoceuticals—signed a memorandum of understanding with the Utah Office of Energy Development. The MOU covers exploration of a test reactor site at the Utah San Rafael Energy Lab and supports engagement with the DOE and NRC, adding substance to the merger narrative. For Mangoceuticals shareholders, who would own just 4% of the combined company, any progress on Nuclea's technology directly impacts the value of that stake. While the MOU does not guarantee regulatory approval or commercial success, it signals institutional support and a potential pathway to deployment.